ELAN Stock Analysis: Buy, Sell, or Hold?
ELAN - Elanco Animal Health Incorporated Common Stock
$24.08
-0.12 (-0.50%)
ā¼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 24, 2026
22d
Get Alerted When ELAN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
š” BUY OPPORTUNITY: ELAN shows positive signals but monitor for confirmation. Market pricing in 1.9% annual growth which appears achievable. Moderate conviction.
š” BUY OPPORTUNITY: ELAN shows positive signals but monitor for confirmation. Market pricing in 1.9% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$31.62
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$19.64
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ELAN is currently trading at $24.08, which is considered slightly high relative to its 30-day fair value range of $22.75 to $24.46. The stock's valuation (Forward PE: 23.4) is in line with its historical norms (22.1). At these levels, the market is pricing in 1.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ELAN is in a strong uptrend. The price is currently testing key support at $23.67. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ELAN is in a strong uptrend. The price is currently testing key support at $23.67. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$22.75 -
$24.46
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.4%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($25.92)
- NEUTRAL: Market pricing in 1.9% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$22.75 -
$24.46
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$23.67
Resistance Level
$25.29
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
23.36
Wall Street Target
$25.92
(+7.7%)
Revenue Growth (YoY)
10.4%
Earnings Growth (YoY)
116.7%
Profit Margin
0.8%
Valuation Premium vs History
+1.9% premium
PE vs Historical
23.4 vs 22.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.9%
(market-implied from PE analysis)
1-Year Target
$24.54
(+2%)
2-Year Target
$25.00
(+4%)
3-Year Target
$25.48
(+6%)
3-Yr Target (if PE normalizes)
(PE: 23ā22)
PE COMPRESSION
$24.10
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.4, Growth: 9.6%)
$31.67
(+32%)
Base:
(SPY PE: 22.3, Growth: 9.6%)
$30.23
(+26%)
Bear:
(PE: 19.0, Growth: 9.6%)
$25.70
(+7%)
š
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (23x PE) as earnings recover.
Forward PE: 23.47 | Forward EPS (Implied): $1.03
Bull Case
$29.08
(+21%)
Analyst growth 15.0%, PE expands to 24.7
Base Case
$24.08
(0%)
Market implied 0.0%, PE stable at 23.5
Bear Case
$18.42
(-24%)
Severe decline -15.0%, PE contracts to 21.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 01, 2026 2:07 AM ET
Data refreshes hourly during market hours. Next update: 3:07 AM
Data refreshes hourly during market hours. Next update: 3:07 AM
š„ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELAN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Val T. Hoyle
SELL
2025-09-23
Ro Khanna
SELL
2025-09-22
Ro Khanna
SELL
2025-08-27
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences Iā¦ |
STRONG BUY
25 analysts |
$179 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$158 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$84 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticalsā¦ |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
Advanced ELAN Option Strategies
Professional options setups generated by AI based on today's ELAN price and gamma walls.
